Swing Away
6年前
However, in reality, since the motivation behind most reverse splits is generally looked at unfavorably by the investment community, these splits often immediately create downward pressure on a stock, whereas a forward split, more often than not, pushes a stock’s price higher in the near term.
REASONS FOR A REVERSE STOCK SPLIT
So, if the market views reverse stock splits with a jaundiced eye, you may ask, why would a company decide to do such a split? The reasons are varied, and include:
1. The desire to increase the share price, especially if the shares are penny stocks. Low prices tend to elicit negative emotions in investors and inhibit the attention of the big money on Wall Street or coverage by major research firms.
2. Companies looking to create spinoffs at attractive prices may use reverse splits. Tyco International (TYC), Motorola Solutions (MSI) and Time Warner (TWX) all employed this strategy when they broke up their companies.
radly
6年前
PharmaMar presents results of trabectedin & doxorubicin for first line treatment of leiomyosarcomas at ASCO 2020
Madrid, June 1st, 2020.- PharmaMar (MSE:PHM) has announced that the final results from the Phase II study of trabectedin in combination with doxorubicin for the treatment of patients with advanced metastatic uterine and soft tissue leiomyosarcoma have been presented in an Oral Abstract Session at the American Society of Clinical Oncology (ASCO) Annual Meeting, that was held on May 29th to 31st, 2020.
Under the title "A single-arm multicenter phase II trial of doxorubicin (Doxo) in combination with trabectedin (Trab) given as first-line treatment to patients with metastatic/advanced uterine (U-LMS) and soft tissue leiomyosarcoma (ST-LMS): Final results of the LMS-02 study" (Abstract 11506), Patricia Pautier, MD, from the Medical Oncology Department, Institut Gustave Roussy, Villejuif, France, has concluded that trabectedin in combination with doxorubicin is an effective first-line treatment for patients with leiomyosarcoma.
The study achieved its primary and secondary endpoints, with a median Progression-Free Survival (PFS) of 10.1 months; a median Overall Survival (OS) of 34.4 months and an acceptable safety profile.
As a reference (not comparable head-to-head studies), the most recent results of other doxorubicin combinations, such as those presented in ASCO 2019 in the “ANNOUNCE” Phase III study (doxorubicin + olaratumumab), reported a median PFS of 6.9 months, and an OS of 21.9 months (ASCO 2019 LBA3)[1].
Patricia Pautier, MD, said: "Combination of doxorubicin and trabectedin constitutes an active first-line therapy for patients with uterine and soft tissue leiomyosarcoma. Results in overall response rate, progression free survival and now in overall survival are very encouraging.” And added: “Results of the LMS04 trial, a randomized phase-III study comparing this combination followed by trabectedin versus doxorubicin alone in 1st-line therapy in metastatic LMS are pending.”
All virtual ASCO poster presentations will be available on request to registered participants for 180 days from May 29th, 2020: https://meetinglibrary.asco.org
radly
6年前
OTHER RELEVANT INFORMATION
The Executive Committee of Pharma Mar, S.A., as authorized by the Company's Board of Directors, has decided to implement the Free of Charge Stock Ownership Plan approved by resolution of the Annual General Shareholders' Meeting of 26 June 2019 (Agenda Item Fifth), authorizing the Board of Directors (or the Executive Committee or director or person delegated by the Board) to deliver up to a maximum of 500,000 shares free of charge. This Plan is intended exclusively for employees and officers of the Pharma Mar Group, and under no circumstances may the members of the Board of Directors of Pharma Mar, S.A. be eligible as beneficiaries, even if they hold executive positions in any Group companies.
The essential conditions established for free delivery of the shares are specified below:
Share lockup system. A lockup system shall be established for the shares distributed to the prevent disposal thereof. This lockup system shall likewise apply to those shares acquired by the beneficiary free of charge and which by means of any corporate transaction have their origins in previously held shares of this type.
The lockup period shall remain in force for three years ("Loyalty Period") from the time of effective delivery of the shares.
Notwithstanding the above, a portion of the shares shall be unblocked a year and half after delivery of the shares; in particular, the lockup shall be lifted from the number of shares equal to total shares distributed divided by a coefficient established by the Executive Committee based on the performance levels of each employee in 2019 (meeting targets established for the year), as based on the information provided in such regard by the Pharma Mar Group companies employing each of the beneficiaries. The shares distributed shall enjoy full political and economic rights.
Condition subsequent for distribution of shares. Delivery of the shares to each beneficiary is subject to a condition subsequent, which shall be deemed met in the case of voluntary resignation, fair dismissal of the beneficiary or leave (excluding in the case of leave covered
by Law 39/1999, of 5 November, on the promotion of employee work-life balance, or by Organic Law 3/2007, of 22 March, on effective gender equality, in which case the Loyalty Period shall be extended for the length of the leave), provided said circumstances arise prior to the end of the Loyalty Period. In the event of termination of the employment relationship between a beneficiary and its employer for reasons other than the above, the Loyalty Period shall be deemed fulfilled, unless the employment relationship was terminated so that a new relationship could be established between the beneficiary and another Pharma Mar Group company.
This condition subsequent shall apply to the shares that should have remained locked up through the end of the Loyalty Period (i.e. shares that should have, in theory, remained locked up for a period of three years). Compliance with this condition shall have no retroactive effects.
The condition subsequent having been met, the affected shares shall be returned, following the same procedure used for acquisition, to Pharma Mar, S.A. or, by request thereof, to the subsidiary employing the beneficiary.
In accordance with the foregoing, the Executive Committee has agreed to deliver shares for a total value of €592,063.61, with a share reference value equal to the lower of: a) the weighted average change in the share price of Pharma Mar, S.A. on the continuous market for 28 April 2020; b) the simple average change in the daily weighted average change in the share price of Pharma Mar, S.A. on the continuous market for the previous month (i.e. between 28 March 2020 and 28 April 2020, both inclusive). The share value calculated in this manner shall be used exclusively for the purpose of determining the number of shares to be delivered to each beneficiary, which will under no circumstances exceed €12,000 per beneficiary. This value therefore does not constitute a price of any kind.
The reference value was finally established at €4.6108, corresponding to the simple average change in the daily weighted average change in the share price of Pharma Mar on the continuous market for the previous month, as this amount was less than the weighted average change in the share price of Pharma Mar on the continuous market for 28 April 2020, which was equal to €5.7696.
Once the final reference value has been established, the total number of shares to be delivered to the beneficiaries, free of charge, was finally established at 128,408 shares (0.0577% of share capital).
The shares shall be delivered via a change in ownership (Article 83 of the restated text of the Securities Market Act approved by Royal Legislative Decree 4/2015, of 23 October), which is expected to take place in the coming days, once the relevant accounts have been opened for the beneficiaries of the Plan.
radly
6年前
Why is this down on this great report? Revenues and profits up and debt down.
PharmaMar Group presents results for the first quarter 2020
PharmaMar Group recorded a net profit of €70.6 million in the first quarter.
Sales revenues in the first quarter of 2020 increased by 35% to €24.8 million.
Sales of Yondelis® in the first quarter rose 21% to €20.7 million.
Total revenues for the first quarter of 2020 amounted to €99 million, compared with €19.4 million for the first quarter 2019.
Madrid, April 23rd, 2020. – PharmaMar Group (MSE: PHM) recorded total sales revenues of €24.8 million for the first quarter of 2020. This represents a growth of 35% compared with the first quarter of last year. Of the above total, €20.7 million correspond to net sales of Yondelis®, which includes €2.3 million of raw material sales to partners. Total sales of Yondelis® increased 21% with respect to the first three months of 2019. In the quarter ending March 31st, 2020, diagnostic sales increased by 44% to €1.9 million, reflecting the launch of the COVID-19 diagnostic test in the second half of March.
With reference to income from licenses, a total of €73.9 million was registered as of March 31st. On January 21st, 2020, PharmaMar received the $200 million (€181 million) upfront payment from Jazz Pharmaceuticals in connection with the licensing agreement signed in December 2019, which came into force in January 2020. In application of the regulations on revenue recognition (IFRS 15), €73.0 million of this payment was recorded in the first quarter of 2020.
PharmaMar Group's total debt at the end of the first quarter of 2020 was reduced to €60.5 million from €82.7 million at the end of 2019. The Group ended the first quarter with a cash and cash equivalents position of €173.6 million.
PharmaMar Group net profit amounted to €70.6 million to March 31st, 2020, compared with €10.4 million deficit at the same time last year.
radly
6年前
PharmaMar Group presents results for the first quarter 2020
PharmaMar Group recorded a net profit of €70.6 million in the first quarter.
Sales revenues in the first quarter of 2020 increased by 35% to €24.8 million.
Sales of Yondelis® in the first quarter rose 21% to €20.7 million.
Total revenues for the first quarter of 2020 amounted to €99 million, compared with €19.4 million for the first quarter 2019.
Madrid, April 23rd, 2020. – PharmaMar Group (MSE: PHM) recorded total sales revenues of €24.8 million for the first quarter of 2020. This represents a growth of 35% compared with the first quarter of last year. Of the above total, €20.7 million correspond to net sales of Yondelis®, which includes €2.3 million of raw material sales to partners. Total sales of Yondelis® increased 21% with respect to the first three months of 2019. In the quarter ending March 31st, 2020, diagnostic sales increased by 44% to €1.9 million, reflecting the launch of the COVID-19 diagnostic test in the second half of March.
With reference to income from licenses, a total of €73.9 million was registered as of March 31st. On January 21st, 2020, PharmaMar received the $200 million (€181 million) upfront payment from Jazz Pharmaceuticals in connection with the licensing agreement signed in December 2019, which came into force in January 2020. In application of the regulations on revenue recognition (IFRS 15), €73.0 million of this payment was recorded in the first quarter of 2020.
PharmaMar Group's total debt at the end of the first quarter of 2020 was reduced to €60.5 million from €82.7 million at the end of 2019. The Group ended the first quarter with a cash and cash equivalents position of €173.6 million.
PharmaMar Group net profit amounted to €70.6 million to March 31st, 2020, compared with €10.4 million deficit at the same time last year.
radly
6年前
PharmaMar has submitted a Phase II clinical trial of Aplidin® (plitidepsin) for the treatment of COVID-19 to the Spanish Medicines Agency
The objective of the trial is to evaluate the efficacy and safety of plitidepsin as a treatment for COVID-19 (SARS-CoV-2) in hospitalized patients.
Plitidepsin, which is approved in Australia for the treatment of multiple myeloma, has also demonstrated efficacy as an antiviral in in vitro studies conducted at the CSIC's National Biotechnology Center against the human coronavirus HCoV-229E, and previously against other types of virus at the Carlos III Health Institute.
Madrid, April 2nd, 2020. PharmaMar (MSE:PHM) has announced that on March 24th the APLICOV clinical trial protocol for Aplidin® (plitidepsin) was submitted to the Spanish Medicines and Healthcare Products Agency (AEMPS). This is a multicenter, randomized Phase II clinical trial, in which two different doses of plitidepsin will be evaluated for the treatment of patients with COVID-19 pneumonia. The protocol is currently being evaluated.
The protocol includes 160 patients admitted to hospitals in Spain, where it is intended to assess whether plitidepsin, administered intravenously for 5 days to patients with COVD-19 pneumonia, reduces the proportion of patients who progress to Acute Respiratory Distress Syndrome (ARDS), the main cause of patients requiring mechanical ventilation and/or admission to Intensive Care Units.
Several Spanish centers are due to participate in the study and which is expected to start as soon as the authorization from the Health Authorities is obtained.
On March 13th, the Company announced the results of in vitro studies of plitidepsin in human coronavirus HCoV-229E, with a mechanism of multiplication and propagation that is very similar to that of SARS-CoV-2. The studies were carried out at the National Biotechnology Centre of the Spanish National Research Council (CSIC) by Dr. Luis Enjuanes, Dr. Sonia Zúñiga and Dr. Isabel Solá (see press release).
According to José María Fernández, President of PharmaMar, "This health emergency requires us all to work together to stop this pandemic. Each of us is obliged to do our utmost". He added, "As soon as we receive authorization from the AEMPS, we will be able to start the clinical trial with plitidepsin and we hope that it can become an effective weapon against COVID-19".
Plitidepsin acts by blocking the protein eEF1A, present in human cells, which is used by SARS-CoV-2 to reproduce and infect other cells. By means of this blocking, the reproduction of the virus inside the cell is prevented, making its propagation to the rest of the organism’s cells, unfeasible.
radly
6年前
Madrid, 25 March 2020
In accordance with article 226 of the recast Spanish Securities Market Act (Ley del Mercado de Valores), approved by Royal Legislative Decree 4/2015 of 23 October, article 2 of the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the conditions applicable to buy-back programmes and stabilisation measures (the “Delegated Regulation”) and concordant provisions, is hereby reported the following
INSIDE INFORMATION
It is hereby informed that, under the authorization granted by the General Shareholders' Meeting held on June 26, 2019 for the derivative acquisition of treasury shares, Pharma Mar,
S.A. (the “Company”) has agreed to carry out a program to buy-back treasury shares under the terms indicated below (the “Buy-back Program”).
The Buy-back Program will be carried out in accordance with the provisions of article 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC (“Market Abuse Regulation”) and the Delegated Regulation:
Purpose: the Buy-back Program is intended:
To reduce the Company's share capital by amortizing the shares acquired by virtue thereof, thus improving the earnings per share and contributing to the shareholder's remuneration;
To comply with the obligations derived from the Share Plans for executives and employees of the Group.
Maximum number of shares and cash amount: the Buy-back Program will affect a maximum of 6,679,478 shares, representing approximately 3% of the Company's share capital on the date of this announcement, and its maximum cash amount amounts to € 30,000,000.00. The Company will dedicate (A) a maximum of 4,879,478 shares, representing approximately 2.19% of the Company's share capital on the date of this resolution, for the purpose described in section (a)(i) above and (B) a maximum of 1,800,000 shares, representing approximately 0.81% of the Company's share capital on the date of this resolution, for the purpose described in section (a)(ii) above.
The shares acquired in the exercise of the Buy-back Program until reaching the number of 1,800,000 shares will be destined for the purpose provided in section (a)(ii) above, while the following shares that are acquired until reaching the amount maximum of 6,679,478 shares will be destined for the purpose provided in section (a)(i) above.
Price and volume conditions: the shares will be purchased at market price, in accordance with the price and volume conditions established in article 3 of the Delegated Regulation and, in particular:
Maximum acquisition price: the Company will not purchase shares at a price higher than the highest of the following: (A) the price of the last independent transaction; or (B) the highest independent offer at that time in the trading venues where the purchase is made.
Maximum volume: the Company will not purchase on any trading day more than 25% of the average daily volume of the shares of the Company traded in the 20 business days prior to the date of each purchase in the trading center where the purchase is made.
Duration: The Buy-back Program will have a maximum duration of one year, beginning on April 1, 2020 and remaining in effect until March 31, 2021. However, the Company may terminate the Buy-back Program if, prior to the effective date, it had acquired the maximum number of shares or the maximum cash amount authorized by the Board of Directors referred to in section (b) above or if any other circumstance that so advises occurs.
The interruption, termination or modification of the Buy-back Program, as well as the stock purchase operations carried out by virtue thereof, will be duly communicated to the National Securities Market Commission in accordance with the provisions of the Market Abuse Regulation and the Delegated Regulation.
The Buy-back Program will have JB CAPITAL MARKETS, SOCIEDAD DE VALORES,
S.A.U. as its main manager.
The reduction of the Company's share capital by means of the amortization of the shares acquired under the Buy-back Program for such purposes will be subject to the execution of the capital reduction by the Board of Directors under the resolution that will be proposed to the next General Shareholders’ Meeting.
Likewise, to enable the start of the Buy-back Program operation, the Company has agreed to temporarily suspend, with effect from April 1, 2020, the liquidity contract signed with JB CAPITAL MARKETS, SOCIEDAD DE VALORES, S.A.U., which entered into force on June 5, 2018, as communicated to the market through a relevant event dated June 4, 2018 (registration number 266,399).
radly
6年前
PharmaMar reports positive results for Aplidin® against coronavirus HCoV-229E
These studies have been carried out at the National Biotechnology Centre (Centro Nacional de Biotecnología) of the Spanish National Research Council (CSIC).
PharmaMar will contact regulatory authorities to analyze the possibilities of studies on patients infected with Covid-19.
Madrid, March 13th, 2020. PharmaMar (MSE:PHM) reports that the in vitro studies results of Aplidin® (plitidepsin) on the human coronavirus HCoV-229E, which has a multiplication and propagation mechanism very similar to Covid-19, have been positive with a potency of the nanomolar order. These studies have been carried out at the National Biotechnology Centre (Centro Nacional de Biotecnología) of the Spanish National Research Council (CSIC) by Dr Luis Enjuanes, Dr Isabel Solá and Dr Sonia Zúñiga.
These results confirm the hypothesis that the therapeutic target of Aplidin® (plitidepsin), which is EF1A, is key to the multiplication and spread of the virus.
With these data, PharmaMar will contact regulatory authorities to analyze the possibilities of studies on patients infected with Covid-19.
radly
6年前
Another good day here.
PharmaMar Group's GENOMICA diagnostic kits for COVID-19 coronavirus receive CE conformity marking
GENOMICA will market two products, both validated in clinical samples and with the CE conformity marking:
CLART® COVID-19 (based on GENOMICA's CLART® technology). This technology is capable of simultaneously analyzing 96 samples in less than 5 hours
qCOVID-19 (based on Real Time technology).
GENOMICA is the first Spanish company to obtain the CE marking for the diagnosis of COVID-19 coronavirus.
Madrid, March 6th, 2020.- PharmaMar (MSE:PHM) has announced that GENOMICA, the molecular diagnostics Company belonging to the PharmaMar Group, has obtained the CE conformity marking for its COVID-19 (SARS-CoV-2) coronavirus diagnostic kits. The CE conformity marking certifies that GENOMICA meets the essential requirements described in Directive 98/79/EC on in vitro diagnostic medical devices.
GENOMICA has successfully completed the tests carried out on patient samples, in collaboration with the Carlos III Health Institute, from Madrid. GENOMICA diagnostic kits are highly sensitive and specific in detecting the coronavirus COVID-19, so the virus could be detected even before the patient shows symptoms.
The kits are now available commercially, and these being compatible with the two most widely used diagnostic technologies in hospitals and healthcare centers: CLART® from GENOMICA and Real Time PCR.
CLART® technology has the capacity to simultaneously analyze 96 patient samples in less than 5 hours, making it a diagnostic option for screening of the virus within the population.
GENOMICA is already in contact with the different health authorities to provide these diagnostic kits given the demand generated by the health emergency due to the COVID-19 infection.
In addition, GENOMICA already has commercial agreements in more than 30 countries, including China, where it can now start distributing these kits.
With extensive experience in the detection of respiratory pathogens, the Company currently markets a diagnostic kit for the detection of 21 different viruses associated with respiratory diseases, including the three most frequently detected coronaviruses in humans (HCoV-229E, HCoV-OC43 and HCoV-NL63). Coronaviruses are an extended family of viruses that can cause the common cold, but also serious diseases such as Severe Acute Respiratory Syndrome (SARS) and Middle Eastern Respiratory Syndrome (MERS).
Due to this global health emergency, reliable diagnostic tools are needed to have a rapid response, to quickly provide adequate treatment to patients and to prevent the spread of the virus to the general population.
radly
6年前
Nice day!
Madrid, March 3, 2020
In accordance with Article 226 of the recast Spanish Securities Market Act (Ley del Mercado de Valores), is hereby reported the following:
INSIDE INFORMATION
In response to the news that appeared in the media after the press conference called by the Company today, the Company reports that it has a therapeutic compound, Aplidin, approved in Australia for the treatment of multiple myeloma, which by its mechanism of action could be effective in treating the current outbreak of coronavirus, called Covid-19. This hypothesis is based on scientific publications that show that the virus (its N nucleoprotein) needs the EF1A protein, present in human cells infected by the virus, to reproduce and/or spread within them. Aplidin would block EF1A and make the reproduction of the virus inside the cell unfeasible.
Based on this hypothesis, the Company plans to carry out the corresponding laboratory confirmation tests during the next month. If results confirming this hypothesis are obtained, they will be forwarded to the competent regulatory authorities to decide on the next steps to be taken, in order to continue development in this indication.
Further information: click here.
radly
6年前
Why the big drop today on this news?
Lurbinectedin receives Orphan Drug designation from the TGA for Small-Cell Lung Cancer in Australia
Madrid, February 19th, 2020. PharmaMar (MSE:PHM) has announced that the Australian Therapeutic Goods Administration (TGA), has designated Orphan Drug status to lurbinectedin for the treatment of Small-Cell Lung Cancer (SCLC).
On May 17th, 2017, PharmaMar and Specialised Therapeutics Asia Pte, Ltd (STA) announced an agreement to market lurbinectedin in Australia, New Zealand and in 12 Asian countries (Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Papua New Guinea, Philippines, Singapore, Timor-Leste, Thailand and Vietnam).
SCLC is a very aggressive cancer that is usually diagnosed with advanced, often metastatic disease, thus limiting the role of traditional approaches and usually posing a worse prognosis when compared to other lung cancers[1]. In Australia and New Zealand, approximately 15% of lung cancers are Small Cell[2]. More than 15,000 new cases of lung cancer are recorded in the above countries every year[3].
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
メールアドレスで登録
